Showing results (261-270 of 336) with videos related to
Sort By:
Pageof 34
Clinical Lung Cancer|June 18, 2017
A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L StudyHidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, et al.Lung Cancer (Amsterdam, Netherlands)|February 12, 2025
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studiesHiroaki Akamatsu, Tomomi Nishikawa, Yuriko Takeda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2018
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung CancerChee Khoon Lee, Sally Lord, Ian Marschner, et al.ESMO Open|November 16, 2016
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinibKoichi Azuma, Tomonori Hirashima, Nobuyuki Yamamoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutationsHiromichi Ebi, Isao Oze, Takayuki Nakagawa, et al.JTO Clinical and Research Reports|March 20, 2026
Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and StrategiesMontse Sanchez-Cespedes, William W Lockwood, Kenichi Suda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisChee Khoon Lee, Yi-Long Wu, Pei Ni Ding, et al.Nagoya Journal of Medical Science|March 23, 2007
Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in JapaneseDaisuke Tanaka, Asahi Hishida, Keitaro Matsuo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2009
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutationsSatoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, et al.Cancer Science|September 2, 2016
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanibMasaaki Hibi, Hiroyasu Kaneda, Junko Tanizaki, et al.Pageof 34